A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

J, Astermark; SM, Donfield; DM, DiMichele; A, Gringeri; SA, Gilbert; J, Waters; E, Berntorp

doi:10.1182/blood-2006-04-017988

Public

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Shared by NobleBlocks on Sep 21, 2006 • 12:00 AM UTC

Authors:

Astermark J

Donfield SM

DiMichele DM

Abstract

The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!